Navigation Links
Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
Date:5/17/2009

ATS 2009, SAN DIEGOCystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease, according to researchers at Parion Sciences in Durham, N.C.

The research will be presented on Sunday, May 17, during the American Thoracic Society's 105th International Conference in San Diego.

"Our results suggest that we have identified a new agent that acts directly on a specific pathway, which is involved in the development of cystic fibrosis," said lead author Andrew Hirsh, Ph.D., senior director of drug discovery and preclinical development for Parion Sciences.

In normal respiration, the moist surface of the airway allows individuals to effectively clear mucous, keeping airways open and viable. But in individuals with cystic fibrosis, the hydration level of the airway is altered and the airway mucous builds up, interfering with normal respiration. One of the mechanisms causing airways to not clear mucous correctly in these patients involves the body's natural homeostasis of sodium which, when absorbed too quickly from the surface of the airway, causes moisture to become absorbed too quickly.

"Cystic fibrosis patients have a genetic ion transport defect, which decreases the hydration level on the airway surface and therefore reduces the body's ability to effectively clear mucous, which is a primary defense mechanism of the respiratory system," Dr. Hirsh said. "Diminished mucous clearance leads to chronic respiratory infection and impaired pulmonary function. Currently there are no therapies available to specifically target this channel in patients with cystic fibrosis."

The aerosol-based therapy uses a specific epithelial sodium channel-blocking agent called GS-9411, which prevents sodium from being absorbed across the airway, allowing the surface to remain moist. The increase in moisture allows individuals to more effectively clear the airway of mucous and infectious agents.

This study was performed during the pre-clinical stage of development to compare GS-9411 to an established epithelial sodium channel blocker, called amiloride. Currently, GS-9411 is in Phase I clinical trials being conducted by Parion's development partner, Gilead Sciences, Inc., in Foster City, CA.

During the study, researchers applied GS-9411 to airway surface cells grown in the laboratory, and assessed the potency and reversibility of the drug on these cells. Results of the study indicated GS-9411 allowed the cells to retain liquid for more than eight hours. Concurrent animal studies revealed that the agent enhanced mucous clearance for more than four hours.

The results offer new hope for cystic fibrosis sufferers, according to Dr. Hirsh. "The potency and the length of time that the drug was effective in cells and in animal studies was an outstanding feature that distinguishes this compound from other agents," he said.

The clinical phase of the drug development cycle will enable researchers to continue to refine the treatment for eventual distribution to cystic fibrosis patients.

"GS-9411 administered by aerosol can effectively increase airway surface liquid and enhance mucous clearance in an animal model," he said. "The results demonstrate that GS-9411 warrants further investigation as a new drug therapy to decrease respiratory infection and improve pulmonary function."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets
2. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
3. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
4. Grocery Manufacturers Association Releases Science Policy Paper on Sodium and Salt
5. Sodium, Potassium Intake Tied to Heart Disease
6. Consumer Reports Identifies Foods With Surprisingly High Levels of Sodium
7. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
8. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
9. Low-sodium advice for asthmatics should be taken with a pinch of salt
10. Low-sodium advice for asthmatics should be taken with a grain of salt
11. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in ... a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular ... has leant his presence to an educational purpose as the host of the “Informed” ... being cancer. In a recent episode, the series focuses on thyroid cancer. , Although ...
(Date:4/27/2017)... ... 2017 , ... Healthcare companies are trying to meet talent shortages and find ... executive resume. , “If you’re a healthcare executive open to new opportunities this year ... as ready as you are for a new job search. I’ve heard from countless ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Goodcents Deli ... open in the Lincoln, Neb. area this year. , The first new location ... The second location will open at 84th and Northern Lights Drive this fall. And ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology: